Physician profile
Rustin W Crawford
NPI 1659419091
$1,552.00
in general payments reported to CMS, 2019-2025
27 companies · $67.91 in 2025
The $67.91 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $263 · 2020: $74.01 · 2021: $357 · 2022: $574 · 2023: $136 · 2024: $80.24 · 2025: $67.91.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $284.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $301.51 | 2021-2023 | Vraylar |
| Abbott Laboratories | $186.49 | 2020-2025 | Freestyle Libre 3, Prodigy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.35 | 2019-2023 | Jardiance |
| Boston Scientific Corporation | $137.13 | 2019-2024 | Watchman Flx, Superion Indirect Decompression System |
| Pfizer INC. | $116.24 | 2019 | |
| Novo Nordisk INC | $75.71 | 2020-2021 | |
| Astrazeneca Pharmaceuticals Lp | $68.41 | 2019-2023 | Farxiga |
| Biohaven Pharmaceutical Holding Company Ltd. | $64.12 | 2022 | |
| Amgen INC. | $44.00 | 2021-2025 | Krystexxa |
| Glaxosmithkline, LLC. | $39.37 | 2019-2022 | |
| Nevro Corp. | $34.43 | 2022 | |
| Impulse Dynamics (USA) INC. | $30.61 | 2023-2024 | Optimizer, Optimizer |
| Janssen Pharmaceuticals, INC | $30.28 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $28.08 | 2022-2023 | |
| Lilly USA, LLC | $25.12 | 2019-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $23.09 | 2023 | Intellis Adaptivestim |
| Vanda Pharmaceuticals INC. | $22.07 | 2022 | |
| Novartis Pharmaceuticals Corporation | $18.94 | 2022 | |
| Astellas Pharma US INC | $18.36 | 2023 | Myrbetriq |
| Takeda Pharmaceuticals U.S.A., INC. | $18.06 | 2019 | |
| Allergan, INC. | $17.90 | 2019 | |
| Lucid Diagnostics INC. | $16.16 | 2022 | |
| Alfasigma USA, INC. | $16.11 | 2021 | |
| Merck Sharp & Dohme LLC | $14.70 | 2020 | |
| Axonics, INC. | $14.36 | 2022 | |
| Inspire Medical Systems, INC. | $13.98 | 2025 | Inspire |
| Medtronic USA, INC. | $13.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rustin Crawford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.